GENENTECH, INC.;THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人:
BENET, LESLIE Z.,DALZIEL, GENA,DEAN, BRIAN,DRESSER, MARK,FRYMOYER, ADAM,HOLDEN, SCOTT,JIN, JIN,WARE, JOSEPH A.
申请号：
CA2849331
公开号：
CA2849331A1
申请日:
2012.10.12
申请国别(地区):
CA
年份:
2013
代理人:
摘要：
Changes in gastric pH due to oral co-administration of acid-reducing agents, such as proton pump inhibitors, and oncology drugs can have a marked impact on the absorption and oral bioavailability of the oncology drug if the pH decreases the maximal absorbable dose. Moreover, there is a potential for specific drug-drug interactions between some of the acid-reducing agents and these drugs. Methods are described for treating patients on gastric acid-reducing therapy with orally-administered PI3K inhibitor compound GDC-0941. Treatment with a re-acidification compound during treatment with GDC-0941 improves bioavailability of GDC-0941.
